GLP1R and metabolic dysfunction-associated steatotic liver disease: We postulate that the long-term use of NSAIDs may subsequently contribute to or even lead to further expanding the growing pandemic of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), and obesity by affecting GLP-1 production as a first step and subsequently hepatic insulin activity and glucose production.